

» PŘEHLEDOVÉ ČLÁNKY

KONSOLIDAČNÍ LÉČBA BRENTUXIMAB VEDOTINEM U PACIENTŮ S RELABUJÍCÍM/REFRAKTERNÍM KLASICKÝM HODGKINOVÝM LYMFOMEM PO PROVEDENÍ AUTOLOGNÍ TRANSPLANTACE HEMATOPOETICKÝCH KMENOVÝCH BUNĚK V ČESKÉ REPUBLICE

s relapsem/progresí klasického Hodgkinova lymfomu na principu eradikace zbytkové nemoci. Po letech zkušeností z reálné klinické praxe můžeme konstatovat, že tato indikace

brentuximabu naplňuje svůj potenciál a významně zlepšuje vyhlídky pacientů po ASCT na dosažení trvalé remise za cenu přijatelné a obvykle dobře řešitelné toxicity.

LITERATURA

1. Brice P, DeKerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398:1518-1527.
2. Samara Y, Mei M. Autologous Stem Cell Transplantation in Hodgkin Lymphoma – Latest Advances in the Era of Novel Therapies. Cancers. 2022;14:1738.
3. SPC Adcetris. Available from: www.sukl.cz. [online] [cited: 24.03.2023].
4. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862.
5. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639-2642.
6. Akay OM, Ozbalak M, Pehlivan M, et al. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter

- retrospective study. Hematol Oncol. 2021;39(4):498-505.
7. Massaro F, Pavone V, Stefani PM, et al. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Hematol Oncol. 2022;40(1):31-39.
8. Marouf A, Cottreau AS, Fouquet G, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. 2022;107(7):1681-1686.
9. Martinez C, de Haro ME, Romero S, et al. Impact of pre-and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Ann Hematol. 2023;102:429-437.
10. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
11. Common Terminology Criteria for Adverse Events (CTCAE)

MH CZ – DRO (FNOI, 00098892) AZV
NU22-03-00182 from Ministry of Health of the Czech Rep. and research project Cooperatio which are awarded by the Charles University in Prague.

Version 5.0 Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.

12. Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
13. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562-1566.
14. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390:2790-2802.
15. Driessen J, Tonino SH, Moskowitz AJ, et al. How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Hematology Am Soc Hematol Educ Program. 2021(1):240-246.

PIŠTE JAKO PROFESIONÁL

Zkontrolujte si, jestli ve svých prezentacích, člancích atd. neděláte zbytečné chyby

Ty nejtypičtější
jsme pro vás sepsali
a vysvětlili na sociálních
sítích a našem webu. →



~~COVID-19~~

~~Covid-19~~

✓ covid-19

V době pandemie covidu-19 došlo k...

~~20tiletá pacientka~~

~~20-tiletá pacientka~~

~~20-letá pacientka~~

✓ 20letá pacientka

SOLEN MEDICAL EDUCATION